Ecto-ATPase CD39 Inactivates Isoprenoid-Derived Vγ9Vδ2 T Cell Phosphoantigens

Cited by papers we hold 3

• Gamma delta T-cell-based immune checkpoint therapy: attractive candidate for antitumor treatment · 2023
  No notice
• Improving the Efficiency of Vγ9Vδ2 T-Cell Immunotherapy in Cancer · 2018
  No notice
• Tregs: Where We Are and What Comes Next? · 2017
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.